Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update Interim data from Phase 2 KINETIC clinical trial of KIN001 to treat hospitalized COVID-19 patients expected in Q3 2022First patient dosed with in Phase 2 KINFAST clinical trial with ambulatory...

Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients KINFAST to evaluate ability of KIN001 to reduce severity and duration of symptoms in ambulatory COVID-19 patientsInterim data from ongoing Phase 2 KINETIC trial in hospitalized Covid-19 patients...

Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville Financing to be drawn in tranchesFinancing will enable Kinarus to advance the clinical development of KIN001 Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS)...